Patents Assigned to Eolas Therapeutics, Inc.
  • Halo-substituted piperidines as orexin receptor modulators
    Patent number: 11434236
    Abstract: The present application relates to certain halo-substituted piperidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.
    Type: Grant
    Filed: December 9, 2020
    Date of Patent: September 6, 2022
    Assignees: ASTRAZENECA AB, EOLAS THERAPEUTICS, INC.
    Inventors: Theodore M. Kamenecka, Jörg Holenz, Steven Wesolowski, Yuanjun He, Roland Bürli
  • Halo-substituted piperidines as orexin receptor modulators
    Patent number: 10894789
    Abstract: The present application relates to certain halo-substituted piperidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: January 19, 2021
    Assignees: ASTRAZENECA AB, EOLAS THERAPEUTICS, INC.
    Inventors: Theodore M. Kamenecka, Jörg Holenz, Steven Wesolowski, Yuanjun He, Roland Bürli
  • Difluoropyrrolidines as orexin receptor modulators
    Patent number: 10221170
    Abstract: The present application relates to certain difluoropyrrolidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: March 5, 2019
    Assignee: Eolas Therapeutics, Inc.
    Inventors: Theodore M. Kamenecka, Yuanjun He
  • Substituted prolines/piperidines as orexin receptor antagonists
    Patent number: 9896452
    Abstract: The present invention is directed to compounds that modulate the bioactivity of an orexin receptor such as OX1 or OX2, or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated; and to methods of preparation of compounds of the invention.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: February 20, 2018
    Assignee: EOLAS THERAPEUTICS, INC.
    Inventors: Theodore M. Kamenecka, Yuanjun He, William Nguyen, Rong Jiang, Xinyi Song, Robert Jason Herr, Qin Jiang
  • Substituted prolines / piperidines as orexin receptor antagonists
    Patent number: 9499517
    Abstract: The present invention is directed to compounds that modulate the bioactivity of an orexin receptor such as OX1 or OX2, or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated; and to methods of preparation of compounds of the invention.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: November 22, 2016
    Assignee: Eolas Therapeutics, Inc.
    Inventors: Theodore M. Kamenecka, Yuanjun He, William Nguyen, Rong Jiang, Xinyi Song, Robert Jason Herr, Qin Jiang
  • Substituted prolines/piperidines as orexin receptor antagonists
    Patent number: 9440982
    Abstract: The present invention is directed to compounds that modulate the bioactivity of an orexin receptor such as OX1 or OX2, or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated; and to methods of preparation of compounds of the invention.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: September 13, 2016
    Assignee: Eolas Therapeutics, Inc.
    Inventors: Theodore M. Kamenecka, Yuanjun He, Rong Jiang, William Nguyen, Xinyi Song, Robert Jason Herr, Qin Jiang